Malignant pleural mesothelioma (MPM) is an aggressive cancer that affects the lining of the lungs and is primarily caused by exposure to asbestos. It has a poor prognosis, with limited treatment options and a median survival of less than a year in advanced stages. However, recent studies involving combination immunotherapies have shown promising results in improving patient outcomes. This article explores the positive follow-up immune response and survival data observed in the completed Phase 1 study of Galinpepimut-S combined with Opdivo in advanced MPM, conducted by SELLAS Life Sciences.
SELLAS Life Sciences recently reported noteworthy findings from their completed Phase 1 study of Galinpepimut-S in combination with Opdivo (nivolumab) in patients with advanced MPM. The primary endpoint of safety and efficacy was met, with clinical activity and increased survival rates observed.
Galinpepimut-S, also known as GPS, is a novel peptide-based cancer vaccine that targets the Wilms’ tumor 1 (WT1) antigen - a protein overexpressed in MPM cells. The vaccine aims to stimulate the body’s immune system to identify and destroy cancer cells expressing the WT1 antigen. Opdivo, on the other hand, is a checkpoint inhibitor that enhances the immune response by blocking the programmed cell death protein 1 (PD-1) pathway, thereby allowing T-cells to attack cancer cells more effectively.
In the Phase 1 study, a total of 40 patients with advanced MPM were enrolled. The combination therapy demonstrated a strong safety profile, with no dose-limiting toxicities reported. Moreover, encouraging clinical activity was observed, as evidenced by a disease control rate of 85% and a partial response rate of 25%. These results are highly promising, considering the limited treatment options available for MPM.
Additionally, the study showed a significant immune response to both Galinpepimut-S and Opdivo. Specifically, the combination therapy induced the expansion of WT1-specific T-cells, as well as increased levels of programmed death-ligand 1 (PD-L1) expression on tumor cells. This immune activation is likely to contribute to the observed clinical activity and improved survival outcomes.
During the follow-up period, an extended median survival time of 16.4 months was reported for patients receiving the combination therapy. Notably, this surpassed the historical median survival rate associated with standard-of-care treatments, such as chemotherapy and radiation therapy. The prolonged survival observed in this study underscores the potential of Galinpepimut-S and Opdivo combination therapy as a novel treatment approach for advanced MPM.
Conclusion:
The positive outcomes from the completed Phase 1 study of Galinpepimut-S combined with Opdivo in advanced MPM offer a glimmer of hope for patients facing this devastating disease. The combination immunotherapy demonstrated both a favorable safety profile and encouraging clinical activity, leading to increased survival rates beyond the current standard of care.
Further research is warranted to validate these findings in larger, controlled clinical trials. If successful, this combination therapy could potentially revolutionize the treatment landscape for MPM and provide an additional therapeutic option for patients with limited treatment options.
In conclusion, the results from this study highlight the remarkable promise of combination immunotherapy in the fight against advanced MPM. Collaborative efforts between researchers, clinicians, and pharmaceutical companies, such as SELLAS Life Sciences, are crucial in advancing the field of oncology and improving patient outcomes.
Comments